braasch biotech llc privately held company specializes development biopharmaceutical vaccine products human veterinary healthcare markets specifically braasch developed worlds first antiobesity vaccine also researching applications growth hormone deficiency type diabetes braasch biotech llc incorporated state south dakota total focus developing somatostatin vaccines related addition developing testing somatostatin vaccine technology variety species different metabolic conditions company also expanded worldwide intellectual property positions multiple filings anticipates several additional filings support somatostatin also known growth hormone inhibiting hormone main regulator release growth hormone gh pituitary gland leads several body functions including increase insulinlike growth factor levels somatostatin inhibits actions growth hormonereleasing hormone also hypothalamus hormone controls release growth hormone braaschs somatostatin vaccine technology allows immune system temporarily reduce eliminate mostly inhibitory actions somatostatin vaccination effect causes growth hormone released turn stimulates release liver hormone cascade help address issues relating obesity type diabetes since growth hormone deficiencies lead increased risk human applications braasch biotech focused human obesity type diabetes applications along growth hormone deficiencies disorders veterinary field braasch developed vaccines increase livestock productivity reduce obesity pets dogs cats horses applicability gh treatments currently pursued many pharmaceutical companies variety human conditions based success drug treatments time braasch pursue additional applications intellectual property vaccination approach eg development myocardial infarction httpsenwikipediaorgwikibraaschbiotech